Royalty Pharma RPRX Net margin
Net margin at other companies
Other financials
Where this comes from
Calculated from Royalty Pharma’s reported figures.
Based on trailing twelve months.
The official record: Royalty Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Royalty Pharma's net margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Royalty Pharma's net margin?
- Royalty Pharma (RPRX) reported net margin of 33.9% in Q1 2026.
- How has Royalty Pharma's net margin changed year-over-year?
- Royalty Pharma's net margin decreased by 29.8% year-over-year, from 48.3% to 33.9%.
- What is the long-term trend for Royalty Pharma's net margin?
- Over 2 years (2021 to 2025), Royalty Pharma's net margin has grown at a -23.6% compound annual growth rate (CAGR), from 270.4% to 157.7%.
- What does net margin mean?
- The share of every sales dollar that becomes bottom-line profit.
- How do you interpret net margin?
- Higher is better, but net margin mixes operating performance with financing and tax effects and one-off items — read it alongside operating margin to separate the operating story from the rest.
- How does net margin compare across companies?
- Comparable across peers but sensitive to leverage and tax structure; two operationally identical firms can show different net margins purely from financing.